Artículo

Mitigation of acute seizures and neuropathology after traumatic brain injury by structure-based discovery-identified drugs

Kajevu, Natalie ; Bañuelos, Ivette ; Andrade, Pedro ; Hämäläinen, Elina ; Sabatier, Laureano Leonel Icon; Couyoupetrou, Manuel ; Villalba, Maria Luisa Icon; Gavernet, Luciana Icon; Lipponen, Anssi ; Natunen, Teemu ; Puhakka, Noora ; Hiltunen, Mikko ; Talevi, Alan Icon; Pitkanen, Asla

Otros responsables

Fecha

04/2025

Editorial

Mary Ann Liebert

Revista

Journal of Neurotrauma

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0897-7151

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Our objective was to test the hypothesis that structure-based identified or designed compounds exhibiting neuroprotective, antioxidant, and anti-inflammatory properties in vitro will mitigate early seizures and neuropathology after traumatic brain injury (TBI) in vivo. The neuroprotective and antiinflammatory effects of 11 compounds identified by computer-assisted approximations were tested in vitro in neuronal microglial co-cultures. Among these, compound FBA exhibited the best neuroprotective (MAP-2, a neuronal damage biomarker), antioxidative (nitrite production), and antiinflammatory (TNF-α) effects in vitro [all p<0.01]. Consequently, its neuroprotective and antiseizure effects were assessed in vivo in adult male Sprague-Dawley rats exposed to severe lateral fluidpercussion-induced TBI. Rats under continuous video-electroencephalogram (vEEG) monitoring received prophylactic treatment with an intraperitoneal (i.p.) injection of FBA (FBApro, 30 mg/kg) or vehicle (VEH, 48% PEG in 0.9% saline, 3 ml/kg) at 2 and 24 h post-TBI. Rats that developed status epilepticus received 1-2 additional on-demand FBA doses (FBApro+, 100 mg/kg, i.p.) to stop epileptiform activity. FBApro treatment reduced the cortical lesion area (18.9 ± 4.1 mm2 , n=7) compared with VEH treatment (24.8 ± 5.7 mm2 , n=10, p<0.05). FBApro treatment also showed a favorable effect on white matter by reducing plasma levels of pNF-H, a biomarker of axonal injury, compared with VEH treatment (Cohen’s delta 0.657). Both FBApro (368 ± 407 s) and FBApro+ (256 ± 327 s) treatments reduced the average cumulative seizure duration compared with VEH (896 ± 703 s, both p<0.05). The FBApro+ treatment regimen also reduced the mean relative theta and alpha power and increased the mean relative gamma power in the EEG (p<0.05). Our data identified FBA as a novel structure-based discovered compound with promising favorable effects on structural and functional recovery after TBI.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa